FDA clears Numelvi, adding a new JAK option for itchy dogs: full analysis

Merck Animal Health is entering the canine itch market with a new talking point for veterinarians: differentiation on age, selectivity, and vaccine logistics. On February 25, 2026, the FDA approved Numelvi (atinvicitinib tablets) for control of pruritus associated with allergic dermatitis in dogs 6 months of age and older, making it the newest oral option in a therapeutic area that remains central to small animal practice. (merck.com)

The timing matters because canine dermatology has already seen significant regulatory turbulence. In September 2024, FDA approved Elanco’s Zenrelia (ilunocitinib tablets) for allergic dermatitis and atopic dermatitis in dogs at least 12 months old. But FDA soon followed with a Dear Veterinarian letter emphasizing boxed-warning language around vaccine-induced disease risk, inadequate immune response to vaccines, opportunistic infections, hematologic changes, and observed neoplastic conditions in clinical studies. Those warnings made vaccination timing and case selection a major part of prescribing discussions. (fda.gov)

Against that backdrop, Numelvi arrives with a cleaner practical message. Merck says the product is a once-daily, first-line treatment that reduces itch from the first dose, is at least 10 times more selective for JAK1 than JAK2, JAK3, and TYK2 in in vitro assays, and can be used in dogs as small as 4.4 lb. The U.S. label covers pruritus associated with allergic dermatitis in dogs from 6 months of age, which is younger than Zenrelia’s original FDA-approved age threshold. Merck and dvm360 also highlighted that clinics won’t need to adjust vaccination schedules when using Numelvi, a point that appears designed to address a real pain point created by Zenrelia’s rollout. (merck.com)

There’s also a broader market and evidence story developing here. Merck has already said Numelvi received a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products in June 2025, suggesting the company has been building a multinational launch strategy. On the evidence side, peer-reviewed publications are easier to find for ilunocitinib than for atinvicitinib so far. PubMed lists 2025 studies showing ilunocitinib efficacy and field safety in client-owned dogs with allergic dermatitis and atopic dermatitis, while publicly accessible atinvicitinib data appear to be concentrated more in company materials, congress abstracts, and launch communications at this stage. That relative gap matters in a profession that is paying close attention to emerging research more broadly, including residency and fellowship work such as the UC Davis VIRRS presentations on fungal diagnostics and canine neurodegenerative biomarkers—an example of how quickly clinically relevant evidence can move from training programs into practice conversations. (merck.com)

Merck’s launch messaging leaned heavily on convenience and positioning. In company materials, Christine McKinney, DVM, DACVD, said Numelvi offers a first-of-its-kind option for veterinary professionals, while Tim Kowalski of Merck framed second-generation JAK inhibition as an approach already familiar in human medicine. Those are company voices rather than independent commentary, but they signal how Merck intends to compete: not just on efficacy, but on workflow, safety perception, and use in younger dogs. Independent expert reaction was limited in the sources surfaced, though dvm360’s coverage echoed the same differentiators, especially age eligibility and lack of vaccine schedule changes. The product is also launching into a practice environment where client affordability and reimbursement logistics are getting more attention, with recent industry moves expanding direct pet insurance reimbursement to CareCredit accounts for some plans and publications offering veterinarians more guidance on how to discuss insurance with clients. For chronic dermatology cases that often require repeat visits and long-term medication decisions, those operational details can shape uptake as much as label language. (merck.com)

Why it matters: For veterinary professionals, this is less about one more itch tablet and more about how treatment algorithms may shift. Chronic allergic dermatitis is high-volume medicine, often managed in general practice before referral, and drug selection affects recheck schedules, vaccine planning, adverse-event monitoring, and client adherence. If Numelvi performs in practice as advertised, some clinicians may see it as an appealing option for younger dogs, for cases where vaccination timing complicates Zenrelia use, or for pet parents who want an oral alternative with a straightforward dosing story. At the same time, the limited amount of peer-reviewed, post-approval U.S. data currently available for atinvicitinib means many clinicians will likely wait for broader real-world experience and published comparative evidence before changing established protocols. That caution may be especially understandable in a profession already juggling other system-level pressures, from technician support and scope-of-practice debates to affordability conversations with clients. That last point is an inference based on the current mix of regulatory, workforce, and publication evidence. (merck.com)

What to watch: The next signals will be Numelvi’s spring 2026 commercial rollout, whether Merck publishes pivotal U.S. trial data in peer-reviewed journals, and how quickly practices incorporate the product into allergy pathways alongside Apoquel, Cytopoint, Zenrelia, diet trials, parasite control, and infection management. Also worth watching is whether Numelvi’s launch changes how clinics talk with pet parents about vaccination timing, monitoring, long-term dermatology care, and the financial planning that often accompanies chronic disease management. (dvm360.com)